Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis

International Journal of Antimicrobial Agents

Volumn 25, Issue 3, 2005, Pages 237-246

  Buchanan, P ^a   Roos, K ^b   Tellier, G ^c   Rangaraju, M ^d   Leroy, B ^d  

^a River Road Medical Group   (United States)

^b Capio AB   (Sweden)

^c Zoom International   (Canada)

^d SANOFI   (France)

Author keywords

Acute maxillary sinusitis; Ketolide; Resistance; Respiratory pathogens; Telithromycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BACTERIAL ENZYME; BETA LACTAMASE; CEFUROXIME AXETIL; ERYTHROMYCIN; PENICILLIN G; TELITHROMYCIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIOLOGY; BACTERIUM ISOLATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXILLA SINUSITIS; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA AND VOMITING; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE;

EID: 14344261323     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.12.002     Document Type: Article

References (44)

1. J.G. Bartlett IDCP guidelines: management of upper respiratory tract infections Infect Dis Clin Pract 6 1997 212 220
2. E.R. Wald Microbiology of acute and chronic sinusitis in children and adults Am J Med Sci 316 1998 3 20
3. J.C. Vogan, W.E. Bolger, and A.S. Keyes Endoscopically guided sinonasal cultures: a direct comparison with maxillary sinus aspirate cultures Otolaryngol Head Neck Surg 122 2000 370 373
4. W. Sokol Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program Am J Med 111 Suppl. 9A 2001 10S 24S
5. I. Brooks, WM. Gooch 3rd, and S.G. Jenkins Medical management of acute bacterial sinusitis: recommendations of a clinical advisory committee on pediatric and adult sinusitis Ann Otol Rhinol Laryngol 182 2000 2 20
6. Sinus and Allergy Health Partnership Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Otolaryngol Head Neck Surg 123 2000 S1 S32
7. W.N. Sokol Considerations in diagnosis and treatment of sinusitis Antibiot Clin 3 Suppl. 1 1999 29 38
8. K.L. Evans Diagnosis and management of sinusitis BMJ 201 1994 1415 1422
9. C. Thornsberry, D.F. Sahm, and L.J. Kelly Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST surveillance program Clin Infect Dis 34 Suppl. 1 2002 S4 S16
10. D. Felmingham Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective resistant organism tracking and epidemiology for the ketolide telithromycin J Infect 44 Suppl. A 2002 3 10
11. M. Pichicero Short courses of antibiotic in acute otitis media and sinusitis infections J Int Med Res 28 Suppl. 1 2000 25A 36A
12. D. Guillemot, C. Carbon, and B. Balkau Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae JAMA 279 1998 365 370
13. G.V. Doern, K.P. Heilmann, H.K. Huynh, P.R. Rhomberg, S.L. Coffman, and A.B. Brueggemann Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995 Antimicrob Agents Chemother 45 2001 1721 1729
14. M.A. Pfaller, A.F. Ehrhardt, and R.N. Jones Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment Am J Med 111 Suppl. 9A 2001 4S 12S discussion 36S-8S
15. A. Bonnefoy, M. Guitton, C. Delachaume, P. Le Priol, and A.M. Girard In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models Antimicrob Agents Chemother 45 2001 1688 1692
16. D.J. Hoban, G.G. Zhanel, and J.A. Karlowsky In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Diagn Microbiol Infect Dis 35 1999 37 44
17. A.L. Barry, P.C. Fuchs, and S.D. Brown Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin) Antimicrob Agents Chemother 42 1998 945 946
18. J. Jalava, J. Kataja, H. Seppala, and P. Huovinen In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species Antimicrob. Agents Chemother. 45 2001 789 793
19. A.P. Johnson, C.J. Henwood, L. Tysall, and M. Warner Activity of the ketolide telithromycin (HMR 3647) against erythromycin-susceptible and -resistant pneumococci isolated in the UK Int J Antimicrob Agents 18 2001 73 76
20. M.I. Morosini, R. Canton, and E. Loza In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms Antimicrob Agents Chemother 45 2001 2427 2431
21. G.A. Pankuch, M.A. Visalli, M.R. Jacobs, and P.C. Appelbaum Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents Antimicrob Agents Chemother 42 1998 624 630
22. M. Wootton, K.E. Bowker, A. Janowska, H.A. Holt, and A.P. MacGowan In vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci J Antimicrob Chemother 44 1999 445 453
23. Felmingham D, Harding I. Telithromycin is highly active against clinical isolates of Streptococcus pneumoniae collected in the PROTEKT study, irresepective of penicillin, macrolide or fluoroquinolone resistance. Poster P-1253 presented at the 11th European Congress of Clinical Microbiology and Infectious Diseases, 1-4 April 2001, Istanbul, Turkey.
24. D.J. Biedenbach, M.S. Barrett, and R.N. Jones Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains Diagn Microbiol Infect Dis 31 1998 349 353
25. T.A. Davies, B.E. Dewasse, M.R. Jacobs, and P.C. Appelbaum In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae Antimicrob Agents Chemother 44 2000 414 417
26. J.A. Barman Balfour, and D.P. Figgitt Telithromycin Drugs 61 2001 815 829
27. P. Buchanan, T. Stephens, and B. Leroy Telithromycin vs cefuroxime axetil in acute maxillary sinusitis Am J Rhinol 17 2003 369 377
28. K. Roos, C. Brunswig-Pitschner, and R. Kostrica Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis Chemotherapy 48 2002 100 108
29. M. Luterman, G. Tellier, B. Lasko, and B. Leroy Efficacy and tolerability of the ketolide telithromycin (HMR 3647) for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in the treatment of acute maxillary sinusitis (AMS) in adults Ear Nose Throat J 82 2003 576 586
30. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing, 14th informational supplement. NCCLS Document M100-S14. Wayne, PA: NCCLS; 2004.
31. A.W. Chow, C.B. Hall, J.O. Klein, R.B. Kammer, R.D. Meyer, and J.S. Remington Evaluation of new anti-infective drugs for the treatment of respiratory tract infections Clin Infect Dis 15 Suppl. 1 1992 S62 S88
32. J.M. Gwaltney Jr., S. Savolainen, and P. Rivas Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis Antimicrob Agents Chemother 41 1997 1517 1520
33. P.A. Johnson, H.P. Rodriguez, and J.J. Wazen Ciprofloxacin versus cefuroxime axetil in the treatment of acute bacterial sinusitis J Otolaryngol 28 1999 3 12
34. R. Siegert, P. Gehanno, and P. Nikolaidis A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults Respir Med 94 2000 337 344
35. Miyamoto N, Murakami S, Yajin K, et al. Pharmacokinetic study of a new ketolide antimicrobial telithromycin (HMR 3647) in otorhinolaryngology [abstract 2144 and poster]. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 2000. Toronto, Canada. Washington DC: American Society for Microbiology; 2000. p. 32.
36. S. Douthwaite, L.H. Hansen, and P. Mauvais Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA Mol Microbiol 36 2000 183 193
37. L.H. Hansen, P. Mauvais, and S. Douthwaite The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA Mol Microbiol 31 1999 623 631
38. L. Xiong, S. Shah, P. Mauvais, and A.S. Mankin A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre Mol Microbiol 31 1999 633 639
39. J.R. Lonks, J. Garau, and L. Gomez Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae Clin Infect Dis 35 2002 556 564
40. T.B. Hyde, K. Gay, and D.S. Stephens Macrolide resistance among invasive Streptococcus pneumoniae isolates JAMA 286 2001 1857 1862
41. F. Namour, D.H. Wessels, M.H. Pascual, D. Reynolds, E. Sultan, and B. Lenfant Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses Antimicrob Agents Chemother 45 2001 170 175
42. P. Kardas Patient compliance with antibiotic treatment for respiratory tract infections J Antimicrob Chemother 49 2002 897 903
43. D.A. Sclar, T.A. Tartaglione, and M.J. Fine Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases Infect Agents Dis 3 1994 266 273
44. A.J. Claxton, J. Cramer, and C. Pierce A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 2001 1296 1310